Entheon Biomedical Corp. announced that Cybin IRL Limited has delivered notice to the Company to terminate the consulting services agreement (the Consulting Agreement) entered into between the Company and Cybin that was announced on July 11, 2022 pursuant to which the Company was to provide ongoing support to the Phase 1 N,N-dimethyltryptamine study. Services under the Consulting Agreement have been fully rendered and fees payable by Cybin to the Company were accelerated as a result of the early termination.